Andrew James Aguirre

Andrew James Aguirre, M.D., Ph.D., is an Associate Professor of Medicine at the Dana-Farber Cancer Institute. His research focuses on pancreatic cancer, KRAS inhibition, and epigenetic vulnerabilities in oncogenic pathways.

• Selected Grants:
  • R01CA276268 (2023-2027): Principal Investigator on KRAS inhibition mechanisms
  • U01CA274276 (2022-2027): Co-Principal Investigator on stromal modulation in pancreatic cancer
  • K08CA218420 (2017-2022): Principal Investigator on epigenetic vulnerabilities

Research Trends: His recent publications emphasize RAS inhibition, transcriptomic plasticity, and metastatic cancer metabolism. Collaborations span institutions like Harvard Medical School, MIT, and University of Texas MD Anderson Cancer Center.

Scientific Networks: Key co-authors include William Hahn, James Cleary, and Benjamin Wolpin. He works across NIH-funded projects targeting pancreatic and gastric cancers.